Print Friendly, PDF & Email

NCT/Study#

NCT04432207 /

IMU-201-101

An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study Of IMU-201 (PD1-Vaxx), A B-Cell Immunotherapy, In Adults With Non-Small Cell Lung Cancer

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: